Clinical Trial Update: Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset [Phase 4]

View source ↗

Summary

The update summarizes a Phase 4 study evaluating the effects of ocrelizumab on cerebrospinal fluid biomarkers at the onset of multiple sclerosis, including rela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome
• Relapsing Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | Phase 4 | Status: ACTIVE_NOT_RECRUITING